Skip to content

Saliva-based transcriptomics for early diagnosis of esophageal squamous cell carcinoma study

Saliva-based transcriptomics for early diagnosis of esophageal squamous cell carcinoma study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500104585
Enrollment
Unknown
Registered
2025-06-19
Start date
2024-01-30
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Squamous cell carcinoma of the oesophagus

Interventions

Gold Standard:Patients with healthy oesophagus were identified by the clinician (investigator) taking into account the patients chief complaint, past medical history, and imaging, and patients with oe
Index test:Salivary exosome KPNA2 gene

Sponsors

Shanghai Changhai Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Inclusion criteria for patients with esophageal squamous cell carcinoma: (1) Confirmed diagnosis of esophageal squamous cell carcinoma; (2) Age >=50 years. 2. Inclusion criteria for healthy patients: (1) Age >=50 years old. (2) Healthy subjects: All healthy subjects were recruited in public places (such as parks, elderly activity centers, shopping areas, or hospital physical examination centers).

Exclusion criteria

Exclusion criteria: Exclusion criteria for oesophageal squamous cell carcinoma patients: (1) Those who have received anticancer treatments such as surgery, radiotherapy and chemotherapy; (2) Combined with other malignant tumours; (3) Combined with serious oral disease, lung disease, renal or hepatic dysfunction, severe hypertension, diabetes mellitus. (3) People with severe oral disease, lung disease, renal or hepatic dysfunction, severe high blood pressure, diabetes; (4) Those who refuse or are unable to sign the informed consent form. Healthy patients exclusion criteria: Healthy controls were excluded if they had any history of cancer, severe oral disease, diabetes mellitus, pulmonary disease, liver and kidney dysfunction, severe immune system changes, etc. Healthy controls with severe immune changes and cardiovascular events in the past 6 months were also excluded.

Design outcomes

Primary

MeasureTime frame
The area under the receiver operating characteristic curve (AUC-ROC);Accuary;Sensitivity;Specificity;

Countries

China

Contacts

Public ContactWang Luowei

Shanghai Changhai Hospital

wangluoweimd@126.com+86 139 0183 3088

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026